RT Journal Article
SR Electronic
T1 748 Phase 1/2 study of the hexavalent OX40 agonist INBRX-106 alone and in combination with pembrolizumab in select solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A844
OP A844
DO 10.1136/jitc-2023-SITC2023.0748
VO 11
IS Suppl 1
A1 Sanborn, Rachel E
A1 Furqan, Muhammad
A1 Laux, Doug
A1 Sharma, Manish
A1 Olson, Daniel
A1 Berz, David
A1 Hauke, Ralph J
A1 Massarelli, Erminia
A1 Steuer, Conor
A1 Davis, Elizabeth
A1 Iams, Wade T
A1 Thompson, Jonathan
A1 Hamm, John
A1 Andrianov, Vasily
A1 O’Neill, Brianne
A1 Durana, Yaiza Diaz De
A1 Tolcher, Anthony W
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_1/A844.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.